BR112013013415A2 - composição farmacêutica, e, método para a preparação de uma composição - Google Patents

composição farmacêutica, e, método para a preparação de uma composição

Info

Publication number
BR112013013415A2
BR112013013415A2 BR112013013415A BR112013013415A BR112013013415A2 BR 112013013415 A2 BR112013013415 A2 BR 112013013415A2 BR 112013013415 A BR112013013415 A BR 112013013415A BR 112013013415 A BR112013013415 A BR 112013013415A BR 112013013415 A2 BR112013013415 A2 BR 112013013415A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
preparing
pharmaceutical
composition
Prior art date
Application number
BR112013013415A
Other languages
English (en)
Inventor
Kyu Kim Dong
Dong Park Hee
Hyeon Juhn Jae
Hyun Kim Ju
Young Jung Min
Sun Kim Ree
Ah Park Soo
Hack Lee Sung
Il Kim Sung
Jae Park Séong
Rin Kim Yoo
Sik Chung Young
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013013415(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of BR112013013415A2 publication Critical patent/BR112013013415A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
BR112013013415A 2010-12-09 2011-12-07 composição farmacêutica, e, método para a preparação de uma composição BR112013013415A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Publications (1)

Publication Number Publication Date
BR112013013415A2 true BR112013013415A2 (pt) 2019-09-24

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013415A BR112013013415A2 (pt) 2010-12-09 2011-12-07 composição farmacêutica, e, método para a preparação de uma composição

Country Status (17)

Country Link
EP (1) EP2648730A4 (pt)
KR (1) KR101414814B1 (pt)
CN (1) CN103249415B (pt)
AR (1) AR084195A1 (pt)
AU (1) AU2011339150B2 (pt)
BR (1) BR112013013415A2 (pt)
CL (1) CL2013001626A1 (pt)
CO (1) CO6721030A2 (pt)
DO (1) DOP2013000115A (pt)
EA (1) EA201390844A1 (pt)
IL (1) IL226449A0 (pt)
MX (1) MX2013005716A (pt)
PE (1) PE20140699A1 (pt)
SG (1) SG190326A1 (pt)
UA (1) UA108277C2 (pt)
UY (1) UY33772A (pt)
WO (1) WO2012077968A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
AU2014230304B2 (en) * 2013-03-12 2018-07-05 Lg Chem, Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
EA013426B1 (ru) * 2003-12-01 2010-04-30 Рекордати Айэлэнд Лимитед Фармацевтические композиции, содержащие лерканидипин
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Also Published As

Publication number Publication date
PE20140699A1 (es) 2014-06-13
UY33772A (es) 2012-07-31
CN103249415B (zh) 2017-12-12
EP2648730A2 (en) 2013-10-16
AU2011339150B2 (en) 2015-09-10
WO2012077968A2 (en) 2012-06-14
EP2648730A4 (en) 2014-08-06
AU2011339150A1 (en) 2013-06-06
WO2012077968A3 (en) 2012-07-26
EA201390844A1 (ru) 2013-11-29
UA108277C2 (ru) 2015-04-10
CN103249415A (zh) 2013-08-14
AR084195A1 (es) 2013-04-24
SG190326A1 (en) 2013-06-28
IL226449A0 (en) 2013-07-31
MX2013005716A (es) 2013-06-12
CL2013001626A1 (es) 2013-10-04
CO6721030A2 (es) 2013-07-31
KR20120089787A (ko) 2012-08-13
DOP2013000115A (es) 2014-07-31
KR101414814B1 (ko) 2014-07-21

Similar Documents

Publication Publication Date Title
BRPI1011764A2 (pt) composição farmacêutica, e, método para preparar uma composição farmacêutica
BR112014015042A2 (pt) composição farmacêutica, e, método para obter uma composição radiofarmacêutica
SMT201700008B (it) Composizione farmaceutica
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BR112012009609A2 (pt) método para fabricar uma dispersão sólida, dispersão sólida , preparação farmacêutica e composições
BRPI0912384A2 (pt) composição, e, método para preparar uma composição
BR112012000623A2 (pt) composição de emulsão estabilizada, método, e, método para preparar uma composição de emulsão estabilizada
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BR112015001098A2 (pt) composto, composição farmacêutica e método para o tratamento de uma condição de doença.
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
DK3246018T3 (da) Farmaceutisk sammensætning
BR112012016912A2 (pt) composição de gel de diagnóstico, método para preparar uma composição de gel de diagnóstico
BRPI1008598A2 (pt) composição farmacêutica para inalação
BRPI1016132A2 (pt) composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável.
BRPI0922173A2 (pt) preparação farmacêutica, e, método para preparar uma preparação farmacêutica
EE201300005A (et) Ravimkoostis
BR112013010738A2 (pt) composto, composição farmacêutica, e, método para tratar uma infecção viral
BR112013008008A2 (pt) composto, composição farmacêutica e processo para preparar um composto
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição
BR112014009889A2 (pt) compostos dissubstituídos, compostos e composição farmacêutica
BRPI1007161A2 (pt) composição farmacêutica oral, e processo para preparar uma composição
BR112014014285A2 (pt) composição, e, método para fabricar uma composição
BR112013012873A2 (pt) processo para preparar uma n, n-dialquiletanolamina
EP2786982A4 (en) AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
BR112013005986A2 (pt) processo para preparar uma composição derivada de estolídeo e composição derivada de estolídeo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.